Sword Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital physical therapy platform. $4B valuation. $240M ARR, cash-flow positive. 2,500+ employers. Founded 2015, Porto/NYC. Raised $340M+. Private.
About
Sword Health is a digital musculoskeletal care company founded in 2015 and headquartered in New York City with engineering roots in Porto, Portugal. The company was founded by physical therapist and engineer Virgílio Bento with the mission of freeing two billion people from pain using AI-powered physical therapy that matches or exceeds the clinical outcomes of in-person care. Sword pioneered the use of sensor-equipped motion trackers combined with AI therapy guidance delivered through a tablet interface.\n\nSword's platform pairs each member with a licensed physical therapist who designs and supervises a personalized program, while an AI engine called Phoenix handles real-time biomechanical coaching during sessions, monitors adherence, and flags clinical concerns for human review. Programs cover the full MSK spectrum — back, neck, shoulder, hip, knee, and post-surgical rehabilitation — as well as pelvic health through its Bloom product. Sword sells to self-insured employers and health plans; it has contracted with more than 2,500 enterprise customers including major Fortune 500 companies.\n\nSword reached $240 million in annualized recurring revenue and achieved cash-flow positivity, a rare milestone among digital health companies at its stage. The company has raised more than $340 million in total funding, reaching a $4 billion valuation. Its clinical evidence base — spanning dozens of peer-reviewed studies demonstrating meaningful pain reduction and return-to-work rates — differentiates Sword in a crowded MSK market and supports its position as the leading AI-native physical therapy platform.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.